Seattle biotech company raises $100 million
Seattle-based Umoja Biopharma has raised a $100 million Series C round. With the funding, announced Tuesday, Umoja wants to ...
Durham biotech startup raises $175 million as it starts novel gene therapy trial
It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.
ncbiotech.org1d
Durham's Tune Therapeutics raises $175M in venture capital
Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.
precisionmedicineonline2d
Tune Therapeutics Raises $175M in Series B Financing to Fund Hepatitis B Epigenetic Silencing Drug
Its lead candidate Tune-401, which aims to repress viral DNA that contributes to infection, has entered into clinical trials in New Zealand and Hong Kong.
Axios on MSN2d
Durham biotech firm Tune Therapeutics has raised a $175 million funding round
A Durham biotech firm founded on technology built at Duke University has raised $175 million to fund clinical trials of its ...
Seattle biotech startup Tune Therapeutics lands $175M to support clinical research
Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest ...
Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs
Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution ...